UK markets open in 7 hours 27 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
517.93+0.02 (+0.00%)
At close: 4:00PM EST
Sign in to post a message.
  • R
    Ron
    ARKG
    REGENERON PHARMACEUTICALS is on the sixth largest position
    REGN 758,766 shares or 392,987,674.38$ 3.75%

    ARKK
    REGENERON PHARMACEUTICALS is on position 47
    REGN 228,832 shares or 118,518,957.76$ 0.53%

    my 2 cents is that ARKK will keep buying as they did on Friday

    what do they know/see that we don't know/see ?
  • E
    EricAZ
    Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses

    "Under the agreement, the government will acquire doses at the lowest authorized dose. The government is obligated to purchase all finished doses supplied by June 30, up to 1.25 million doses total (an agreement value of up to $2.625 billion), and may accept doses after this date at its discretion. A number of factors may impact available finished supply by June 30, including manufacturing considerations and authorized dose levels. Regeneron expects to supply approximately 750,000 finished doses by the end of June based on the 2,400 mg dose level, with the vast majority supplied in the second quarter. Regeneron expects to fulfill the entire 1.25 million targeted doses if the 1,200 mg dose is authorized. "
  • V
    Victor
    Today ARK again bought 84K and 23K shares for ARKK and ARKG funds, respectively -- worth 55 millions, looking great to me.
  • L
    Loan Producer
    Earnings are soon: The government is obligated to purchase all finished doses supplied by Jun 30, which is up to 1.25 million doses in total, and might accept doses after this date at its discretion. The company expects to supply about 750,000 finished doses by the end of June, based on the 2,400 mg dose level, with the vast majority supplied in the second quarter. Regeneron expects to fulfill the entire 1.25 million targeted doses, if the 1,200 mg dose is authorized.
  • A
    Anonymous
    How good is the following update?

    Regeneron Pharmaceuticals (NASDAQ:REGN) -0.6% preliminary FY20 U.S. net product sales of EYLEA (aflibercept) injection of ~$4.95B and Q4 net product sales of EYLEA of ~$1.34B.
    Overall distributor inventory levels for EYLEA in the United States remained within the Company’s one-to-two-week targeted range.
    FY20 U.S. net product sales of casirivimab and imdevimab of ~$184M and Q4 U.S. net product sales of casirivimab and imdevimab of ~$144M.
    The Company expects that the full 300K doses under the previously announced contract with the U.S. government will be fulfilled by the end of February 2021.

    https://seekingalpha.com/news/3650415-regeneron-pharmaceuticals-reports-q4-and-fy20-net-product-sales
  • S
    Sparky
    Another buy upgrade and ARK keeps increasing its position.
  • V
    Victor
    ARK bought $8 million worth of REGN again today.
  • D
    Deepnight
    Additional 1.25 m doses means FDA full approval is close for Regeneron antibody coctail ???
  • M
    Mark
    What is wrong with this stock? Anybody? $28 earnings per share and the stock performs like PFE.
  • V
    Victor
    ARK bought additional 31K shares of REGN, now in top 10 of ARKG fund.
  • V
    Victor
    https://www.recoverytrial.net/for-site-staff/site-set-up-1/data-monitoring-committee-correspondence

    The enrollment of hospitalized patients on REGN-COV2 for the RECOVERY trial in UK increases substantially for the last 2 weeks -- from 1703 to 2610, a 53% increase. The trial appears to be going on nicely.
    Data Monitoring Committee correspondence
    www.recoverytrial.net
  • N
    Nik-Ice
    Oh yeah - been waiting for this!
  • S
    Sam@SD
    I don't understand the movement of the SP. Goes up and comes down. Is it shorts or profit taking?
    Earnings and guidance both will be good and I don't see much rise in SP. Any idea?
  • R
    Rex
    I said over and over again, as soon as the as the spot light shifted away from anything Covid and back to their core business, the stock would rally. Unfortunately some times it's all about the headlines instead of the fundamentals
  • S
    SamIAm
    Stock is soaring in ah on additional 2.6B deal to supply government with additional doses.
  • R
    Robert
    Another down day in spite of encouraging news. Yesterday after the close REGN announced encouraging "initial data" from ongoing phase 1/2/3 trial in hospitalized patients on low flow oxygen. Starting one week after treatment the risk of death or of receiving mechanical ventilation was reduced by half for patients whose immune systems had not yet mounted their own immune response (seronegative). In the placebo group seronegative patients were three times more likely to die compared to seropositive ones. A much larger trial will be required to rigorously characterize the drug's effect. REGN expects the ongoing UK based RECOVERY trial to provide the data. Sounds like very good news to me. For the record my wife and I are 71 and I'm much more concerned about having an effective treatment than whether my stock goes up or down tomorrow.
  • D
    Deepnight
    $REGN | US To Buy Added Regeneron Covid-19 Antibody Cocktail Doses
    -Pact Covers 1.25M Added Doses Of Antibody Cocktail
    -Total Potential US Supply Now Over 1.5M Doses
  • H
    Heavenly Hash
    TheFly: Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says

    Fresenius Medical Care (FMS), which is the largest kidney dialysis provider in the United States,
    said it plans to begin administering Eli Lilly (LLY) and Regeneron (REGN) COVID-19 antibody
    treatments nationwide this week at its facilities, reported Reuters' Deena Beasly. Dialysis
    centers represent "a new path" for delivery of the drugs, which have been approved for emergency
    use but are "facing skepticism and logistical problems in some hospitals," the report said.
  • R
    Ron
    ARKG bought another 148.222 shares,
  • H
    Harry
    Per today's presentation, Q3 sales are approx 2.71B vs Street expectation of 2.46B. That would be a nice beat.

    Details are: Eylea-1.34, Dupixent-1.07, Antibodies-0.2, and Libtayo-0.1B.

    Please add if I have missed out anything. GLTA.